Two companies – Kiadis Pharma and Aradigm – have formally withdrawn pan-EU marketing authorization applications (MAAs) after they were told these were likely to be rejected. A third company, Actelion, has withdrawn an application to extend an indication of an already marketed product.
The MAAs relate to Kiadis Pharma’s lead product and stem cell transplant adjunct, ATIR101, and Aradigm’s inhaled antibiotic,...
Welcome to Pink Sheet
Create an account to read this article
Already a subscriber?